Home › Compare › DLEXY vs ABBV
DLEXY yields 129.03% · ABBV yields 3.06%● Live data
📍 DLEXY pulled ahead of the other in Year 1
Combined, DLEXY + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of DLEXY + ABBV for your $10,000?
Datalex plc develops and sells various distribution and retailing software products and solutions to the airline industry in Ireland, the Americas, the Asia Pacific, the United Kingdom, and rest of European countries. The company operates in two segments, E-Business and TPF Consulting. It offers Datalex Direct, a customer-centric digital commerce product for travel retailing through airlines' direct channels; Datalex Merchandiser that enables airlines to deploy intelligent merchandising strategies across channels and touchpoints, generates ancillary revenue, and optimizes traveler engagement at various point in their journey; Datalex NDC, which provides end-to-end offer and order management for indirect channel using NDC; and Datalex Dynamic, which creates and optimizes capabilities by allowing airlines to build customer centric, contextualized, and personalized offers for air and non-air products. The company also provides Datalex China Shopping and Pricing Engine, an air shopping and pricing solution for Chinese airlines; and Datalex Pricing AI, a real-time pricing product. In addition, it delivers professional and hosting services; and offers online payment processing connectivity services, as well as IT consultancy services to airlines. Datalex plc was founded in 1985 and is headquartered in Dublin, Ireland.
Full DLEXY Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.